Pulse Wave Analysis in Advanced Heart Failure (PWA-HF)
|Left Ventricular Assist Device Heart Failure Intra-aortic Balloon Pump LVAD Clot LVAD-related GI Bleed|
|Study Design:||Observational Model: Case-Only
Time Perspective: Cross-Sectional
|Official Title:||Pulse Wave Analysis in Advanced Heart Failure Patients Before and After Ventricular Assist Device|
- Observation of pulse wave signatures in LVAD patients [ Time Frame: ongoing ]
|Actual Study Start Date:||February 2012|
|Study Completion Date:||December 2016|
|Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|
Intra-Aortic Balloon Pump (IABP) Group
Advanced Heart Failure and/or pre-LVAD surgical patient with IABP
Post-LVAD surgical patients with IABP
LVAD patients 3 months or greater post-implantation undergoing echocardiography
LVAD Event Group
LVAD patients who have developed LVAD thrombosis or GI hemorrhage related to LVAD
LVAD patient with an irregular heartbeat.
Valvular disease group
LVAD patient with valvular heart disease
Normal control group
Healthy participant without any known heart disease (Control group).
Pulse waveforms, especially central pressure waveforms, are predictive of cardiovascular events. Peripheral waveforms have been correlated to central waveforms. Peripheral waveforms can be easily measured through applanation tonometry. In this study the investigators hypothesize:
- That previously established peripheral tonometry techniques would apply to patients with advanced heart failure, including continuous flow LVADs and facilitate serial evaluation of central hemodynamics without invasive monitoring.
- That temporary changes in LVAD speed will be evident in frequency spectrum analysis of peripheral, non-invasive waveforms.
- That clinical events involving LVAD will have characteristic frequency spectra.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01642927
|United States, Minnesota|
|Univeristy of Minnesota Lillehei Heart Institute|
|Minneapolis, Minnesota, United States, 55455|
|Principal Investigator:||Peter Eckman, MD||University of Minnesota - Clinical and Translational Science Institute|